Advanz aims to grow after Concordia switch

Concordia International is looking to invest in licensing and co-development deals, as well as in product and company acquisitions, as it seeks to revive its fortunes under the new Advanz Pharma brand following the completion of a recapitalisation transaction that took place in early September.